AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$ALMS

Pangali Sanam sold $2K of ALMS

Pangali Sanam (Chief Legal Officer) sold 332 shares of ALUMIS INC. (ALMS) at $6.52 on 2026-11-02.

Original reporting
SEC EDGAR · Pangali Sanam
Published Nov 4, 2026, 9:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ALMS
Neutral
high confidence
Mentioned
$ALMS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMSNeutralLow
01

Why it matters

The transaction size ($2.2K) is trivial relative to the company's market cap, so price impact is expected to be negligible.

02

Market read

A routine insider sale with limited materiality; unlikely to affect trading decisions.

03

What to watch

Potential upcoming corporate actions or earnings that are not disclosed in this filing.

Relevance 3/10Novelty 3/10Timing: filing posted after market close on 2026-11-04

Background

Form 4 filings disclose insider transactions and are required by the SEC. This filing reports a small open‑market sale by Alumis' Chief Legal Officer.

Company-level read

Ticker impact

$ALMSNeutralHigh confidence
Context

Chief Legal Officer Pangali Sanam sold 332 shares of Alumis Inc. for $2,164.64 on 2026-11-02, reducing his holdings to 9,415 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

A $2K sale by a C‑level officer is a routine transaction with limited market impact.

Market effects

Sector

No broader sector impact; the sale is company‑specific.

Regional

No regional effect; Alumis trades on US exchanges.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

If the insider sale signals concerns, a contrarian could view the dip as a buying opportunity.

Key entities

  • Company
    Alumis Inc.

    US‑listed provider of cloud‑based software solutions.

  • Individual
    Pangali Sanam

    Chief Legal Officer of Alumis Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ALMS insider trading history →

Related articles

$ALMSMed

Alumis Reports Q3 2026 Results, $94.9 Million Net Loss

Alumis reported Q3 2026 revenue of $1.9M and a net loss of $94.9M. Cash reserves totaled $431.3M, expected to last into Q4 2027. The company plans to submit an NDA for envudeucitinib in plaque psoriasis by Q4 2026, with positive Phase 3 data for scalp psoriasis. A Phase 2b trial in lupus did not meet primary endpoints, but a subgroup showed responses. Alumis will start a Phase 2 trial for A-005 in Parkinson's in 2027.

tradingview.com
$ALMSHigh

Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates

ALUMIS INC. (ALMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. ​ Exhibit 99.1 ​ ​ Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates ​ – New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib’s differentiated clinical profile, including the hig

SEC EDGAR 8-K
$ALMSHighAI 8/10

Alumis (ALMS) Faces Pressure After Clinical Results

Voya MI Dynamic Small Cap Fund reported that its overweight position in Alumis (ALMS) hurt performance due to disappointing clinical trial results. ALMS closed at $6.62 with a $883.74M market cap, up 25.38% over 52 weeks. The fund's Q3 2026 letter cited sector performance variations, with energy, tech, and healthcare outperforming.

finance.yahoo.com